3 ms·
It should be noted that inn that article, the FDA concluded that this meant that the two drugs were no longer bioequivalence. At that point, you don't have a br
by belorn 9y ago
It should be noted that inn that article, the FDA concluded that this meant that the two drugs were no longer bioequivalence. At that point, you don't have a brand and a generic drug but rather two different drugs that just happen to have similar ingredients.
The article do bring up a major issue when the FDA changed their decision in regard to a generic. The market and even the FDA itself is having a problem to address the problem. The doctor is quoted: “If the F.D.A. rules it’s not the same, how can it be sold? I don’t understand the rationale for that happening.”. It is indeed odd and a major complaint about how the FDA managed this case.